Top Markets
#1 TENDIES TENDIES +60.15%
#2 Threshold Network Threshold Network +48.72%
#3 Akedo Akedo +24.88%
#4 Cash Cat Cash Cat +21.86%
#5 Kinetiq Kinetiq +16.38%
#6 OSK OSK +16.37%
#7 Maple Finance Maple Finance +13.27%
#8 Ape and Pepe Ape and Pepe +12.62%
#9 Magma Finance Magma Finance +12.46%
#10 Falcon Finance Falcon Finance +11.62%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
Healios K.K. Healios K.K.

Healios K.K.

4593
Rank in Stocks #17173
Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011,... Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.
Share Price
$1.89
Market Cap
$254.55M
Change (1 day)
-2.03%
Change (1 year)
-48.53%
Country
JP
Trade Healios K.K. (4593)

Category

Healthcare
P/E ratio for Healios K.K. (4593)
P/E ratio as of 2026 TTM: 0
According to Healios K.K. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Healios K.K. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.